The Motley Fool··Adria CiminoEli Lilly's April 10 FDA Decision Could Transform Weight Loss Market, But Patience Pays
Eli Lilly awaits April 10 FDA decision on oral weight loss drug orforglipron, amid $11B quarterly sales from current portfolio. Approval could catalyze gains, but long-term fundamentals matter more than short-term decisions.
LLYNVOFDA approvalGLP-1 drugs